Latest on Pharmaceutical Industry


RiboBio and GE Healthcare enter into a Strategic Partnership for Oligonucleotide Drug Development

At the 5th Canton Nucleic Acids Forum (CNAF) in Guangzhou, China, Guangzhou RiboBio Co., Ltd. ("RiboBio") and GE Healthcare Life Sciences ("GE") held a strategic partnership signing ceremony. The strategic partnership ag..Read More...

Arvinas and Macroceutics Establish DEL Screening Collaboration on Undruggable Targets

Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, and Macroceutics, Inc., today announced the establishment of a multi-target collaboration intended to deliver new c..Read More...



Biopharma Development & Production Week

Grand Hyatt Shanghai,
Informa business


Pharmtech & Ingredients

Crocus Expo IEC,
ITE Moscow

Press Releases

QuVa Pharma Announces Its Ability to Supply Hydromorphone and Morphine Pre-Filled Syringes

There is a nationwide shortage of prefilled syringe presentations of hydromorphone and morphine This shortage is expected to persist for a number of months QuVa Pharma Inc is pleased to announce that it has available .. Read More...

FDA approves first two-drug regimen for certain patients with HIV

The US Food and Drug Administration today approved Juluca the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 HIV1 instead of three or more drug.. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics